Peter Prock becomes non executive director of Nupharm
As already reported, APP advised funds controlled by APAX an the acquisition of Inventfarma and Neuraxpharm – the 2 first companies forming Nupharm. Following the creation of Nupharm, Claudio Albrecht assumed the role of a non executive Director from which he stepped down assuming his role in Stada. To guarantee continuity, Peter Prock assumes this role starting September 2017. Nupharm, a pan-European leader in the treatment of diseases related to the central nervous system (“CNS”), is the strategic combination of five leading specialty pharmaceutical companies: Neuraxpharm (Germany and Poland), Qualigen (Spain), FB Health (Italy), as well as Laboratorios Lesvi and Inke (Spain). NuPharm develops and markets branded, generic and nutraceutical pharmaceutical products, offering a wide range of differentiated and affordable CNS treatment options to healthcare professionals and industry partners. With an international presence in more than 50 countries, the Group also manufactures finished dosage forms and active pharmaceutical ingredients dedicated to CNS and respiratory indications.
Albrecht, Prock & Partners AG
CH-6314 Unteraegeri - Zug, Switzerland